Treatment
Mocertatug rezetecan clinical trials
We’re tracking 6 recruiting studies that include Mocertatug rezetecan, each written for real people, not researchers, below.
Recruiting studies
- NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+ - NCT07684599RecruitingPhase 3
Maintenance treatment for advanced endometrial cancer
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
FukuokaAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT07286331RecruitingPhase 3
New drug vs chemo for advanced endometrial cancer
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
Birmingham, AlabamaAges 18 years+ - NCT07684612RecruitingPhase 3
New drug combo for recurrent ovarian cancer
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Newcastle, New South WalesAges 18 years+ - NCT06796907RecruitingPhase 1/Phase 2
Mocertatug rezetecan with other drugs for advanced solid tumors
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
La Jolla, CaliforniaAges 18 years+
What Mocertatug rezetecan is being studied for
Conditions with recruiting Mocertatug rezetecan studies.
Common questions
- Are there clinical trials studying Mocertatug rezetecan?
- Yes. Clin2 currently lists 6 recruiting studies that include Mocertatug rezetecan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Mocertatug rezetecan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Mocertatug rezetecan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Mocertatug rezetecan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.